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Objectives: The objective was to study changes in the faecal microbiota of patients with uncomplicated urinary
tract infections (UTIs) treated with nitrofurantoin and of non-treated healthy controls using 16S rRNA analysis.
Methods: Serial stool samples were collected from patients receiving nitrofurantoin treatment at different time-
points [before treatment (day 1; T1), within 48 h of end of treatment (days 5–15; T2) and 28 days after treatment
(days 31–43; T3)], as well as from healthy controls. Direct DNA extraction (PowerSoil DNA Isolation Kit, MoBio
Laboratories, Carlsbad, CA, USA) from stool samples was followed by pyrosequencing (454 GS FLX Titanium) of
the V3–V5 region of the bacterial 16S rRNA gene.
Results: Among UTI patients, mean proportions of the Actinobacteria phylum increased by 19.6% in the first
follow-up sample (T2) in comparison with the pretreatment baseline stool sample (T1) (P¼0.026). However, pro-
portions of Actinobacteria reversed to ‘normal’ pre-antibiotic levels, with a mean difference of 1.0% compared
with baseline proportions, in the second follow-up sample (T3). The increase in Actinobacteria was specifically
due to an increase in the Bifidobacteriaceae family (Bifidobacterium genus), which constituted 81.0%
(95% CI+7.4%) of this phylum.
Conclusions: No significant impact was observed other than a temporary increase in the beneficial
Bifidobacterium genus following nitrofurantoin treatment, which supports its reintroduction into clinical use.
Keywords: 16S rDNA, compositional changes, antibiotic resistance, urinary tract infections, 16S rRNA, culture independent, stool,
faecal flora, gastrointestinal flora
Introduction
Nitrofurantoin is a synthetic nitrofuran compound that has been
used for decades for the effective treatment of lower uncompli-
cated urinary tract infections (UTIs).1 Upon oral administration,
most of the nitrofurantoin is rapidly absorbed in the small intestine
and excreted by the kidneys into urine, where it reaches high thera-
peutic concentrations (200 mg/mL).2 So far, clinically significant
resistance in most uropathogens is uncommon.3 However, as a
small amount (6%–13%) of orally administered nitrofurantoin
also reaches the colon,1,4 it might impact the bacterial composition
of the gastrointestinal tract. Nitrofurantoin-resistant strains have
been detected previously in the faeces of both nitrofurantoin-
treated patients and healthy volunteers, although with a very
low prevalence (0.6%–2%).5 As nitrofurantoin targets important
bacterial nitroreductases,3 this low recovery of nitrofurantoin-
resistant strains might be ascribed to an associated fitness cost,
especially in the presence of nitrofurantoin.5 As part of a prospect-
ive cohort study in ambulatory care, we studied the impact of
nitrofurantoin treatment on the gastrointestinal flora of patients
with uncomplicated UTIs (ISRCTN 26797709). An initial screening
of these samples on culture detected very low prevalences
(1.6%–3.3%) of nitrofurantoin-resistant Enterobacteriaceae in
the gastrointestinal flora of nitrofurantoin-treated patients both
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pre- and post-treatment (A. Stewardson, N. Adriaenssens,
S. Coenen, M. Godycki-Cwirko, H. Goossens, B. Huttner,
A. Kowalczyk, C. Lammens, S. Malhotra-Kumar, J. Vervoort and
S. Harbarth, unpublished data). Furthermore, differences in colony
counts of Enterobacteriaceae (susceptible or resistant) either
between UTI patients and controls or between the different time-
points of the patient and control groups were also unremarkable.
The stability of the culturable gastrointestinal flora under nitrofur-
antoin treatment prompted us to investigate in the present study
potential changes in the non-cultured fraction utilizing culture-
independent screening methods.
Methods
Study design and sampling
This study was part of a prospective cohort study carried out in ambulatory
patients with uncomplicated UTI visiting general practices in Antwerp
(Belgium) and Lodz (Poland) between January 2010 and August 2013.
Serial stool samples were collected from patients receiving nitrofurantoin
treatment (100 mg three times daily for 3–15 days, n¼61) before treat-
ment (day 1; T1), within 48 h of end of treatment (days 5–15; T2) and
28 days after treatment (days 31–43; T3). In parallel, stool samples
were also collected from non-antibiotic-treated control patients present-
ing either with minor trauma or for a gynaecological examination to the
outpatient clinics. Of these, five nitrofurantoin-treated patients and four
controls were included in the present study. Exclusion criteria for UTI
patients were: treatment with systemic antibiotics within 2 months or
hospitalization within 30 days; residence in a long-term care facility; cur-
rent urinary catheter; and renal transplant or renal replacement therapy.
The controls and household contacts received no antibiotics during the
study period or 2 months before it. Approval was granted by the Medical
Ethics Committee, University of Antwerp Hospital (B30020109056) and by
the Bioethics Committee, Medical University of Lodz (RNN/127/10/KE).
Subjects provided informed consent.
DNA extraction and 16S rDNA sequencing
We performed a 16S rDNA metagenomic analysis of 15 stool samples from
five nitrofurantoin-treated patients and 12 stool samples from four con-
trols. Total bacterial DNA was directly extracted with a PowerSoil DNA
Isolation Kit (MoBio Laboratories, Carlsbad, CA, USA) according to an
adapted protocol of the Human Microbiome Project.6 From each stool
sample, 2 g was homogenized with 5 mL of MoBio lysis buffer in a stom-
acher, followed by centrifugation for 5 min at 1500 g. Of the resulting
supernatant, 1 mL was transferred to a MoBio Garnet Bead tube and pro-
cessed according to the manufacturer’s protocol. DNA concentration was
measured with a NanoDrop instrument (Thermo Scientific, Waltham, MA,
USA). If the DNA concentration was ,10 ng/mL, an additional concentra-
tion step was included, consisting of precipitation with 0.1 volumes of 3 M
sodium acetate and 2 volumes of 100% ethanol followed by a washing
step with 70% ethanol. 16S rDNA V3–V5 regions were amplified by PCR
using primers V345_341F (CCT ACG GGR SGC AGC AG) and V345_909R
(TTT CAG YCT TGC GRC CGT AC). Purified and quantified PCR products
were pooled in equimolar amounts and sequenced on a quarter plate/seg-
ment with a 454 GS FLX Titanium Sequencer (Roche, Basel, Switzerland)
using Titanium FLX reagents, resulting in 3500 reads with a 400–600 bp
read length on average per sample (Microsynth, Balgach, Switzerland).
Data analysis
Data were analysed using the online server MetaGenome Rapid
Annotation using Subsystem Technology (MG-RAST).7 Raw reads were
preprocessed with default parameters and searched against the rRNA
database using BLAT for rRNA identification,8 with a cluster cut-off value
of 97% identity. The longest sequence of each cluster was used as a rep-
resentative for a BLAT similarity search performed against the M5rna data-
base, integrating RDP II,9 Greengenes10 and SILVA11 (maximum e-value
cut-off, 1×105; minimum identity cut-off, 97%; minimum alignment
length cut-off, 15 bp). Mean proportions and 95% CIs were used to
describe changes in proportions of the 16S rDNA reads assigned to the dif-
ferent phyla present in the stool samples of UTI patients and controls over
the three timepoints. The raw sequence reads generated from this study
were deposited in the European Nucleotide Archive with accession number
PRJEB8375. The effect of nitrofurantoin use on mean proportions of the
different phyla (based on 16S rDNA reads) between and within study
groups for different timepoints was statistically analysed using a general-
ized linear mixed model in SAS (version 9.4).
Results
At baseline (T1), the three most highly represented phyla in
the patient group were the Firmicutes, Verrucomicrobia and
Proteobacteria, with mean proportions of 56.9% (95% CI+21.6),
18.6% (95% CI+31.8%) and 11.2% (95% CI+12.1%), respectively.
In the control group the three most highly represented phyla were
the Firmicutes, Actinobacteria and Verrucomicrobia, with mean
proportions of 46.0% (95% CI+16.6%), 21.9% (95% CI+15.1%)
and 15.1% (95% CI+20.8%), respectively. However, large varia-
tions in proportions of the different phyla existed between indivi-
duals, as is evident from the wide 95% CIs, regardless of study
group or timepoint.
Among UTI patients, mean proportions of Actinobacteria
increased by 19.6% in the first follow-up sample (T2) in compari-
son with the pretreatment baseline stool sample (T1) (P¼0.026)
(Table 1). However, proportions of Actinobacteria reverted to ‘nor-
mal’ pre-antibiotic levels, with a mean difference of 1.0% com-
pared with baseline proportions, in the second follow-up sample
(T3) (Table 1). Further analysis of the 16S rDNA reads revealed that
for four of the five UTI patients the increase in the Actinobacteria
phylum was specifically due to an increase in the Bifidobacteriaceae
family, which constituted 81.0% (95% CI+7.4%) of this phylum.
Furthermore, within Bifidobacteriaceae, all 16S rDNA reads
matched the genus Bifidobacterium, which are beneficial bacteria
commonly used as probiotics in human medicine.12 Besides
Actinobacteria, no other remarkable changes in the faecal micro-
biota were noted either between or within the patient and control
groups. A statistically significant change was observed in the phy-
lum Bacteroidetes between the patient and control groups in the
post-treatment T2 samples (Table 1); however, this change was
also observed within the control group between the T1 and T2 sam-
ples, indicating that this might be ascribed to ‘normal’ variation.
Furthermore, mean proportions of Bacteriodetes in the faecal
microbiota at the three timepoints ranged from 1.6% to 4.6%
and any variations therein were probably too minor to be of clinical
relevance.
Of note, we did not utilize the 16S reads to calculate the abso-
lute number of bacteria assigned to each phylum, but rather com-
pared absolute numbers of 16S rDNA reads assigned to the
different phyla to arrive at mean proportions of the phyla. This
was because of (i) the lack of availability of sequencing data,
and therefore of the 16S copy numbers, for several phyla or gen-
era in the faecal microbiota, and (ii) the reported variations in 16S
copy numbers at various taxonomic levels.13 Furthermore, we
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utilized 454 sequencing (vis-a`-vis Illumina) as it has an advantage
in terms of producing longer read lengths covering multiple
variable regions, which allows more reliable clustering for species
determination.
Discussion
Utilizing a culture-independent approach, the present study did
not show any significant impact of nitrofurantoin treatment on
the faecal microbiota other than a temporary increase in the
Actinobacteria phylum, more specifically in the beneficial
Bifidobacterium genus. In addition to its low impact on the bacter-
ial composition of the gastrointestinal flora, resistance selection
by nitrofurantoin was also minimal, as observed by the low recov-
ery of nitrofurantoin-resistant Enterobacteriaceae from urine and
stools of treated patients.5 This is most likely due to the fitness
costs, observed as growth deficits, associated with acquisition
of mutations in the target genes conferring nitrofurantoin resist-
ance, as shown by us recently.5 Furthermore, a recent epidemio-
logical study on clinical nitrofurantoin-resistant Escherichia coli
strains noted a lack of clonal spread of such isolates in the commu-
nity, reiterating the high fitness costs associated with nitrofurantoin
resistance in E. coli.14
However, despite its favourable profile, nitrofurantoin was ear-
marked as one of the older, potentially useful, but ‘forgotten’ anti-
biotics by the ESCMID Study Group for Antibiotic Policies (ESGAP) in
2006. ESGAP’s review of literature regarding reasons for disappear-
ance of such antibiotics from clinical use revealed a combination of
market failures and failures in production and regulatory processes
with non-availability of narrow-spectrum antibacterials, forcing
clinicians to use broad-spectrum drugs and thus adversely influen-
cing prudent antibiotic-use policies.15 – 17 Reasons for shortages
and market withdrawals of older antibiotics might in turn have
been related to lack of profit for drugs in limited-market areas
(small countries) and increasing regulatory requirements and
Table 1. Changes in mean proportions of 16S rDNA reads assigned to different phyla from baseline and between study groups
Phylum
UTI patients (n¼8) Controls (n¼5) UTI patients versus controls
difference in proportion (95% CI) P difference in proportion (95% CI) P difference in proportion (95% CI) P
Actinobacteria
T1 — — — — 216.5% (235.6 to 2.5) 0.084
T2 19.6% (2.7 to 36.6) 0.026 211.3% (230.3 to 7.6) 0.221 14.4% (24.7 to 33.4) 0.128
T3 1.0% (215.9 to 18.0) 0.899 214.7% (233.6 to 4.3) 0.119 20.8% (219.9 to 18.2) 0.926
Bacteroidetes
T1 — — — — 0.1% (22.2 to 2.3) 0.959
T2 0.5% (21.3 to 2.2) 0.559 2.8% (0.9 to 4.8) 0.008 22.3% (24.5 to 20.1) 0.044
T3 20.3% (22.0 to 1.5) 0.740 1.0% (20.9 to 3.0) 0.271 21.3% (23.5 to 1.0) 0.245
Firmicutes
T1 — — — — 10.9% (219.8 to 41.6) 0.457
T2 29.1% (229.9 to 11.7) 0.365 2.0% (221.3 to 25.3) 0.856 20.2% (230.9 to 30.5) 0.992
T3 21.7% (222.6 to 19.1) 0.862 8.5% (214.8 to 31.8) 0.448 0.7% (230.0 to 31.4) 0.960
Proteobacteria
T1 — — — — 8.2% (21.0 to 17.3) 0.077
T2 25.8% (214.4 to 2.9) 0.175 21.2% (210.9 to 8.5) 0.795 3.6% (25.6 to 12.8) 0.413
T3 22.8% (211.5 to 5.8) 0.496 0.2% (29.5 to 9.9) 0.968 5.2% (24.0 to 14.3) 0.247
Tenericutes
T1 — — — — 22.1% (25.2 to 1.0) 0.166
T2 0.2% (22.3 to 2.7) 0.871 21.5% (24.1 to 1.1) 0.230 20.4% (23.6 to 2.8) 0.786
T3 2.4% (20.4 to 5.1) 0.083 0.7% (21.9 to 3.3) 0.553 20.4% (23.8 to 3.0) 0.801
Verrucomicrobia
T1 — — — — 0.9% (234.2 to 36.1) 0.954
T2 29.4% (235.8 to 17.0) 0.447 8.8% (213.2 to 30.8) 0.392 217.3% (254.2 to 19.7) 0.322
T3 4.8% (218.9 to 28.4) 0.664 6.1% (215.8 to 28.1) 0.548 20.4% (235.7 to 34.9) 0.979
Unclassified
T1 — — — — 20.3% (27.4 to 6.9) 0.936
T2 1.2% (23.1 to 5.4) 0.557 0.3% (24.5 to 5.1) 0.893 0.6% (26.5 to 7.8) 0.856
T3 21.2% (25.5 to 3.1) 0.556 21.9% (26.6 to 2.9) 0.416 0.4% (26.8 to 7.5) 0.909
T1, day 1; T2, days 5–15; T3, days 31–43.
Bold type indicates a statistically significant difference (P,0.05); generalized linear mixed model.
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bureaucracy.16,17 However, with the current escalation in antibiotic
resistance rates and a lack of new antibiotics, nitrofurantoin’s
unique mechanism of action, site specificity, achievement of
high urinary levels and low serum concentrations, and effective-
ness against both Gram-negative and Gram-positive bacteria pro-
vide many advantages in UTI therapy that many of the newer
agents do not.18 Taken together, these data support the reintro-
duction of this antibiotic into clinical use and also prompt the
development of nitrofurantoin derivatives or even of similarly
highly ‘targeted’ antibiotics for other infection sites.
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